L-163,101

• CAT Number: I007550
• CAS Number: 162112-43-8
• Molecular Formula: C23H26F2N6O
• Molecular Weight: 440.50
• Purity: ≥95%
• Synonyms: L-163,101; L 163,101; L163,101.;N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(2-methylpropyl)phenyl]sulfonylbenzamide
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 2-[[6-(3,3-difluoropyrrolidin-1-yl)-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile
• InChI: InChI=1S/C23H26F2N6O/c24-23(25)4-8-31(15-23)22-11-18(17-2-6-30(7-3-17)19-13-32-14-19)10-21(29-22)28-20-9-16(12-26)1-5-27-20/h1,5,9-11,17,19H,2-4,6-8,13-15H2,(H,27,28,29)
• InChIKey: RHFIAUKMKYHHFA-UHFFFAOYSA-N
• SMILES: C1CN(CCC1C2=CC(=NC(=C2)N3CCC(C3)(F)F)NC4=NC=CC(=C4)C#N)C5COC5

L-163,101（Cat No.:I007550）is a selective, small molecule antagonist of the glucagon-like peptide-1 (GLP-1) receptor, primarily studied for its potential in metabolic disorders like type 2 diabetes. By blocking the GLP-1 receptor, L-163,101 prevents the action of GLP-1, a hormone involved in insulin secretion, glucose metabolism, and appetite regulation. This action may help in managing blood sugar levels and controlling weight in diabetic patients. Preclinical studies suggest it could be a valuable therapeutic tool in diabetes treatment, though further clinical trials are needed to assess its safety and efficacy.